FDA grants orphan drug designation to ZB131 for cholangiocarcinoma

The FDA granted orphan drug designation to ZB131 for treatment of cholangiocarcinoma, according to the agent’s manufacturer.ZB131 (ZielBio) is a monoclonal antibody with a high affinity and specificity for cancer-specific plectin. The cell surface protein — identified in a variety of malignancies — is associated with aggressive tumors and poor prognosis, according to a ZielBio-issued press release.ZB131 showed high specific binding to cancer-specific plectin and strong anti-cancer activity in preclinical studies, according to the release.A phase 1/phase 2 trial is underwayRead More